. . we value our readers and are committed to growing our community by encouraging you to add to the discussion. .

he said: "our research shows that people, on average, believe that only 34 per cent of protection claims are paid out by insurance companies. .

erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the .